Pronova BioPharma Selects NNE Pharmaplan To Build New Plant

Lysaker, Norway, Dec 11, 2007 - (Hugin via ABN Newswire) - Pharmaceutical industry expertise combined with fast-track construction capabilities were important factors when Pronova BioPharma selected NNE Pharmaplan to construct the new manufacturing plant in Kalundborg, Denmark.

The agreement between Pronova BioPharma and NNE Pharmaplan will be signed tomorrow and covers engineering, procurement, construction management and validation (EPCMV). It also includes a contract for automation integration, for the construction of a good manufacturing practice (GMP) approved pharmaceutical production unit.

NNE Pharmaplan is known as the leading engineering and consultancy company that focuses exclusively on the pharmaceutical and biotechnological industries. The company also has a solid track record for establishing life science production facilities in a very short time without compromising safety or quality requirements of often complex manufacturing processes, and in full compliance with GMP regulations required for the production of pharmaceutical products.

CEO Tomas Settevik of Pronova commented: "NNE Pharmaplan's industrial expertise and proven fast-track capabilities were important factors when we chose them as our cooperation partner. The time table for this project will enable us to continue our fast growth and meet the accelerating demand for our products."

The decision to invest between NOK 1.45 to NOK 1.7 billion in a second manufacturing site for Pronova has been driven by the strong development in the end-user market for the company's commercialized pharmaceutical product Omacor (Lovaza in the U.S) .

The new plant in Kalundborg will double Pronova's current annual production capacity of 1 200 tons and is expected to be operational with necessary approvals in place from the first half of 2010.

Representatives from NNE Pharmaplan and Pronova BioPharma will sign the contract at a short official ceremony on Wednesday 12 December 2007. The ceremony is open for the press and will take place on Juelsmindevej 5 in Kalundborg, Denmark, at 10.30-11.00 (local time).

Enquiries, please contact: Tomas Settevik, CEO: +47 22 53 48 61 Solveig Hellebust, VP HR and Communications: +47 90 14 96 33

Copyright © Hugin ASA 2007. All rights reserved.

Pronova BioPharma ASA

http://www.pronova.com

ISIN: NO0010382021

Stock Identifier: OSE.PRON